{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '13.4 Appendix 4: Recommendations for Management of Latent', 'Tuberculosis Infection', 'Recommendations for management of latent tuberculosis infection (LTBI) are provided', \"below. If the known source of a subject's LTBI is an individual with drug-resistant TB, these\", 'recommended treatments must be modified after consultation with a certified TB specialist or', 'pulmonologist who is familiar with treating TB, as acceptable per local practice.', 'Adapted CDC Recommendations for Management of Latent TB', 'Drug(s)', 'Duration', 'Interval', 'Comments', 'Isoniazid', '9 months', 'Daily', 'Twice weekly', 'Isoniazid', '6 months', 'Daily', 'This regimen is not preferred for TB prophylaxis', 'and should not be used in this study.', 'Twice weekly', 'Isoniazid and', '3 months', 'Once weekly', 'Rifapentine', 'Rifampin', '4 months', 'Daily', 'Abbreviations: CDC = Centers for Disease Control and Prevention; TB = tuberculosis.', 'a. Use Directly Observed Therapy (DOT).', 'Amendment 2: 06 March 2019', '151', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '13.5 Appendix 5: Protocol Amendment 2 Summary of Changes', 'Amendment 2: 06 March 2019', '152', 'Confidential']\n\n###\n\n", "completion": "END"}